| 14909-6 |
Salicylates |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Salicylates [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14909-6 |
|
|
|
|
Both |
|
|
|
0 |
Salicylates SerPl-sCnc |
|
|
|
Y |
|
2-Hydroxybenzoate; 2-Hydroxybenzoic Acid; DRUG/TOXICOLOGY; Drugs; Level; o-Hydroxybenzoate; o-Hydroxybenzoic Acid; ortho-Hydroxybenzoate; ortho-Hydroxybenzoic Acid; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Sali; Salicilates; Salicylate; Salicylic acid; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 1491-0 |
Glucose^30M post 100 g glucose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --30 minutes post 100 g glucose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1491-0 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 30M p 100 g Glc PO Ur-mCnc |
|
|
|
Y |
|
30M p 100 g Glc PO; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p 100 g Glc PO; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 14910-4 |
Serotonin |
SCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Serotonin [Moles/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14910-4 |
|
|
|
|
Both |
|
|
|
0 |
Serotonin Ser-sCnc |
|
|
|
Y |
|
5-HT; 5-hydroxytryptamine; 5-hydroxytryptophane; C10H12N2O; Chemistry; Enteramine; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 14911-2 |
Sertraline |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Sertraline [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14911-2 |
|
|
|
|
Both |
|
|
|
0 |
Sertraline SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Zoloft |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 14912-0 |
Smudge cells/Leukocytes |
NFr |
Bld |
Pt |
Qn |
Manual count |
|
ACTIVE |
Smudge cells/Leukocytes in Blood by Manual count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
14912-0 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Smudge Cells NFr Bld Manual |
|
|
|
Y |
|
Basket cells; Blood; Cell; Cellularity; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Manl; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; WBC; WBCs; White blood cell; White blood cells; Whole blood |
2.79 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 14913-8 |
Testosterone |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Testosterone [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14913-8 |
|
|
|
|
Both |
|
|
|
0 |
Testost SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Testo; Testos; Testost |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 14914-6 |
Testosterone.free |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Testosterone Free [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
14914-6 |
|
|
|
|
Both |
|
|
|
0 |
Testost Free SerPl-sCnc |
|
|
|
Y |
|
Chemistry; FR; Level; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Testo; Testos; Testost; Testost Free; Testosterone.unconjugated |
2.73 |
1.0k |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 14915-3 |
Theophylline |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Theophylline [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14915-3 |
|
|
|
|
Both |
|
|
|
0 |
Theophylline SerPl-sCnc |
|
|
|
Y |
|
Aminophylline; Biophyllin; Continus; DRUG/TOXICOLOGY; Drugs; Lasma; Level; Nuelin; Phyllocontin; Pl; Plasma; Plsm; Point in time; Pro-vent; QNT; Quan; Quant; Quantitative; Random; Sabidal SR; SerP; SerPl; SerPlas; Serum; Serum or plasma; Slo-Phyllin; Somophyllin; Somophylline; SR; Substance concentration; Theo; Theo-dur; Theolair; Uniphyllin |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 14916-1 |
Thiocyanate |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thiocyanate [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14916-1 |
|
|
|
|
Both |
|
|
|
0 |
Thiocyanate SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 14917-9 |
Thioridazine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thioridazine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14917-9 |
|
|
|
|
Both |
|
|
|
0 |
Thioridazine SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mellaril; Novo-ridazine; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sonapax; SR; Substance concentration; Thioridazine Hydrochloride; Thioril |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 14918-7 |
Thyroglobulin |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyroglobulin [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
14918-7 |
|
|
|
|
Both |
|
|
|
0 |
Thyroglob SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Endocrine; Endocrinology; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Tg; Thyglobulin; Thyroglbn; Thyroglob; Tumor marker |
2.34 |
1.0k |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 14919-5 |
Thyrotropin binding inhibitory immunoglobulins |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Thyrotropin binding inhibitory immunoglobulins [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14919-5 |
|
|
|
|
Both |
|
|
|
0 |
TSH BII Ser Ql |
|
|
|
|
|
Bind; Chemistry; Endocrine; Endocrinology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; TBII; Thyroid stimulating hormone; Thyrotropic hormone; TSH; TSH BII |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 1492-8 |
Glucose^1.5H post 0.5 g/kg glucose IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 0.5 g/kg glucose IV |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1492-8 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 1.5h p .5 g/kg Glc IV SerPl-mCnc |
|
|
|
Y |
|
1 1/2 hours; 1 1/2 HR; 1.5h p .5 g/kg Glc IV; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 14920-3 |
Thyroxine.free |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyroxine (T4) free [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
14920-3 |
|
|
|
|
Both |
|
|
|
0 |
T4 Free SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Endocrine; Endocrinology; FR; FreeT4; FT4; Level; Levothyroxine; Levo-thyroxine; L-thyroxine; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; T4; T-4; T4 Free; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4 |
2.73 |
1.0k |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 14921-1 |
Thyroxine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyroxine (T4) [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14921-1 |
|
|
|
|
Both |
|
|
|
0 |
T4 SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Endocrine; Endocrinology; Level; Levothyroxine; Levo-thyroxine; L-thyroxine; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; T4; T-4; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4 |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 14922-9 |
Toxoplasma gondii Ab.IgA+IgE |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Toxoplasma gondii IgA+IgE Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
MICRO |
|
14922-9 |
|
IA |
|
|
Both |
|
|
|
0 |
T gondii IgA+IgE Ser IA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin A; Immune globulin E; Immunoglobulin A; Immunoglobulin E; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; SUDS; T gondii; Toxo; Toxoplasmosis |
2.56 |
1.0k |
|
|
|
|
|
|
|
k[IU]/L |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 14923-7 |
Toxoplasma gondii Ab |
ACnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Toxoplasma gondii Ab [Units/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
14923-7 |
|
|
|
|
Both |
|
|
|
0 |
T gondii Ab Spec-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; T gondii; To be specified in another part of the message; Toxo; Toxoplasmosis; Unspecified |
2.69 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 14924-5 |
Transfusion reaction |
Imp |
Plas/RBC |
Pt |
Nar |
|
|
ACTIVE |
Transfusion reaction [Interpretation] in Plasma or RBC Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
14924-5 |
|
|
|
|
Both |
|
|
|
0 |
Transf React PlasRBC-Imp |
|
|
|
|
|
BLOOD BANK; Erythrocytes; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Pl; Plasma; PlasRBC; Plsm; Point in time; Random; React; Red blood cells; Red blood corpusles; Report; Rxn; Transf React; Tx |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 14925-2 |
traZODone |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
traZODone [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14925-2 |
|
|
|
|
Both |
|
|
|
0 |
traZODone SerPl-sCnc |
|
|
|
Y |
|
Desyrel; DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Trazon; Trialodine |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 14926-0 |
Triazolam |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Triazolam [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14926-0 |
|
|
|
|
Both |
|
|
|
0 |
Triazolam SerPl-sCnc |
|
|
|
Y |
|
APO-TRIAZO; DRUG/TOXICOLOGY; Drugs; Halcion; Level; Novo-triolam; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 14927-8 |
Triglyceride |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Triglyceride [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
14927-8 |
|
|
|
|
Both |
|
|
|
0 |
Trigl SerPl-sCnc |
|
|
|
Y |
|
Cardio; Cardiology; Chemistry; Heart Disease; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Tg; Trig; Trigly; Triglycerides; Triglycrides |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 14928-6 |
Triiodothyronine.free |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
14928-6 |
|
|
|
|
Both |
|
|
|
0 |
T3Free SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Endocrine; Endocrinology; FR; Free T3; FT3; Level; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; T3; T-3; T3Free; thyroid hormone; Total T3; Triodothyrne |
2.73 |
1.0k |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 14929-4 |
Triiodothyronine.reverse |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Triiodothyronine (T3).reverse [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14929-4 |
|
|
|
|
Both |
|
|
|
0 |
T3Reverse SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Endocrine; Endocrinology; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; REV; Reverse T3; rT3; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; T3; T-3; T3Reverse; thyroid hormone; Total T3; Triodothyrne |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 1493-6 |
Glucose^1.5H post 0.05-0.15 U insulin/kg IV post 12H CFst |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 0.05-0.15 U insulin/kg IV 12 hours fasting |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1493-6 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 1.5h p U/kg Ins IV SerPl-mCnc |
|
|
|
Y |
|
1 1/2 hours; 1 1/2 HR; 1.5h p U/kg Ins IV; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; Calorie Fast; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Fast; Fasting; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HUM; Humulin; IH7; Insul; Lente; Level; Mass concentration; NPH; p 12h fast; PC; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente |
2.34 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 14930-2 |
Triiodothyronine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Triiodothyronine (T3) [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14930-2 |
|
|
|
|
Both |
|
|
|
0 |
T3 SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Endocrine; Endocrinology; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; T3; T-3; thyroid hormone; Total T3; Triodothyrne |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
